Nov. 11 at 5:03 PM
(NASDAQ:
$INM)
@inmedpharma reported
$1.12M in sales for Q1 fiscal 2026, with a net loss of
$1.73M and cash of
$9.3M supporting operations into late 2026. The company advances cannabinoid-inspired therapies including INM-901 for Alzheimer's in preclinical stages, paired with a revenue-producing BayMedica manufacturing unit specializing in rare cannabinoids with ~
$5M annual revenue and ~40% gross margins.
https://prismmarketview.com/inmed-pharmaceuticals-advances-cannabinoid-inspired-therapies-with-real-revenue-and-a-clear-path-to-value/
